8-K: Eledon Reports Strong Tegoprubart Clinical Data, 2025 Results

Eledon Pharmaceuticals announced its full year 2025 financial results and significant clinical progress for its lead drug candidate, tegoprubart, across multiple transplantation programs.

Summary

• Eledon Pharmaceuticals reported its fourth quarter and full year 2025 operating and financial results.
• The company announced updated results from 12 patients with type 1 diabetes treated with tegoprubart following islet transplantation, with 10 out of 10 patients more than four weeks post-transplant achieving 100% insulin independence and a mean HbA1c of approximately 5.35%.
• 24-month follow-up data from the Phase 1b long-term extension study in kidney transplantation continued to support tegoprubart's favorable safety and tolerability profile, with no acute rejection, graft loss, or new-onset diabetes, and an increase in mean eGFR from 67.0 mL/min/1.73 m at 12 months to 74.2 mL/min/1.73 m at 24 months.
• Tegoprubart was granted Orphan Drug designation by the FDA for the prevention of allograft rejection in liver transplantation.
• Research and development (R&D) expenses for 2025 increased to $66.3 million from $52.0 million in 2024, driven by clinical development and manufacturing scale-up.
• General and administrative (G&A) expenses decreased to $17.0 million in 2025 from $18.6 million in 2024, primarily due to lower stock-based compensation.
• Net loss for 2025 was $45.6 million, or $0.52 per basic share, compared to a net loss of $36.2 million, or $0.66 per basic share, in 2024.
• Excluding non-cash gains from warrant liabilities, the net loss for 2025 was $79.1 million, compared to $67.1 million in 2024.
• The company ended 2025 with $22.8 million in cash and cash equivalents and $110.5 million in short-term investments.

Sentiment

Score: 7

Explanation: StockSavvy.ai views this as a positive update for a clinical-stage biotech, driven by strong clinical data and regulatory progress for tegoprubart, despite an increased net loss which is typical for companies in this development phase as they advance their pipeline.

Positives

• Tegoprubart achieved 100% insulin independence in 10 out of 12 type 1 diabetes patients more than four weeks post-islet transplantation, with a low mean HbA1c of approximately 5.35%.
• The Phase 1b long-term extension study for kidney transplantation demonstrated a favorable 24-month safety and tolerability profile, with no acute rejection, graft loss, death, new-onset diabetes, or de novo donor-specific antibody formation.
• Mean estimated glomerular filtration rate (eGFR) increased from 67.0 mL/min/1.73 m at 12 months to 74.2 mL/min/1.73 m at 24 months in kidney transplant patients.
• Tegoprubart received Orphan Drug designation from the FDA for the prevention of allograft rejection in liver transplantation, adding to previous designations for pancreatic islet cell transplantation and ALS.
• Basic earnings per share improved to $(0.52) in 2025 from $(0.66) in 2024, despite an increased net loss.
• General and administrative expenses decreased in 2025, primarily due to lower stock-based compensation.

Negatives

• Net loss increased to $45.6 million in 2025 from $36.2 million in 2024.
• Research and development expenses increased significantly to $66.3 million in 2025 from $52.0 million in 2024, indicating higher cash burn.
• Total current assets decreased to $135.7 million in 2025 from $143.7 million in 2024.
• Weighted-average common shares outstanding increased substantially to 81,836,246 in 2025 from 48,543,787 in 2024, indicating significant shareholder dilution.

Risks

• The company has a short operating history and may experience shifts in its business strategy.
• The company has incurred operating losses since inception and may continue to do so.
• There is a need for additional funding to develop the lead drug candidate, and the ability to secure such funding on acceptable terms or at all is uncertain.
• Issuances of common stock could lead to dilution or a decline in the stock price.
• The ability to successfully develop product candidates is not guaranteed.
• Unfavorable global economic and financial market conditions could impact operations.
• The regulatory environment of the business and the ability to obtain required regulatory approvals pose risks.
• Results of non-clinical studies and early clinical trials may not be predictive of results of later-stage clinical trials.
• Delays or difficulties in enrollment of patients in clinical trials could occur.
• The ability to attract and retain executives and key employees is crucial.
• Legislation of the pharmaceutical and healthcare industries could impact the business.
• Cybersecurity and data privacy risks are present.
• The ability of products to achieve marketing approval is uncertain.
• Competition in the industry is a factor.
• The ability to obtain insurance coverage is a risk.
• Dependence on contract research organizations (CROs) introduces risks.
• The ability to protect intellectual property is critical.
• Public health crises could impact operations.
• The ability to maintain proper and effective internal control over financial reporting is essential.

Future Outlook

Eledon Pharmaceuticals anticipates several important milestones in the upcoming year, including receiving FDA guidance on the Phase 3 trial design for tegoprubart in kidney transplantation, followed by the initiation of the Phase 3 trial pending regulatory alignment. The company also expects to report long-term data from its Phase 1 and Phase 2 BESTOW studies in kidney transplantation, and receive FDA regulatory guidance on the path to market for tegoprubart in islet cell transplantation and xenotransplantation. Additionally, Eledon plans to initiate investigator-led studies evaluating tegoprubart for organ rejection prevention in patients with renal dysfunction receiving islet cell transplants, de novo liver transplants, and for kidney transplant tolerance induction.

Management Comments

• David-Alexandre C. Gros, M.D., CEO, stated that Eledon has made significant progress advancing tegoprubart as a potential next-generation immunosuppressive therapy across multiple transplantation settings.
• Dr. Gros highlighted that the over 100 patients treated across transplantation programs provide growing evidence reinforcing the conviction that tegoprubart can address key safety and efficacy issues with current standard-of-care transplant immunosuppression.
• Dr. Gros anticipates multiple important milestones this year, including regulatory engagement for Phase 3 kidney transplantation development, initiation of an additional islet transplantation trial in type 1 diabetes, and the start of a clinical trial in liver transplantation.

Industry Context

StockSavvy.ai notes that Eledon Pharmaceuticals is positioning tegoprubart as a next-generation immunosuppressive therapy, aiming to address key safety and efficacy challenges associated with current standard-of-care treatments in organ transplantation. This places the company in a competitive but high-demand segment of the biotechnology industry, where innovation in reducing rejection and improving long-term graft survival is critical. The positive clinical data, particularly in islet cell and kidney transplantation, suggests tegoprubart could offer a differentiated profile, potentially reducing side effects like nephrotoxicity commonly seen with existing immunosuppressants like tacrolimus.

Stakeholder Impact

• Shareholders: Potential for increased long-term value due to strong clinical data and regulatory milestones, but also face dilution from increased shares outstanding and the risk of future capital raises.
• Patients: Significant positive impact through the potential development of a safer and more effective immunosuppressive therapy for various organ transplantations, including type 1 diabetes, kidney, and liver transplants.
• Employees: Increased R&D activities and personnel growth indicate job stability and expansion within the company.
• Regulatory Authorities: Ongoing engagement with the FDA for guidance on trial designs and market pathways, reflecting the company's commitment to regulatory compliance and product approval.

Next Steps

• Receive FDA guidance on Phase 3 trial design for tegoprubart in kidney transplantation.
• Initiate Phase 3 trial for tegoprubart in kidney transplantation, pending regulatory alignment.
• Report long-term data from Phase 1 and Phase 2 BESTOW studies evaluating tegoprubart in kidney transplantation.
• Receive FDA regulatory guidance on path to market for tegoprubart in islet cell transplantation and xenotransplantation.
• Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients with renal dysfunction receiving an islet cell transplant.
• Initiate an investigator-led study evaluating tegoprubart for the prevention of organ rejection in patients receiving a de novo liver transplant.
• Initiate an investigator-led study evaluating tegoprubart for kidney transplant tolerance induction.

Key Dates

Recommendation

Eledon Pharmaceuticals presents a mixed financial picture with increased net losses, partially offset by an improved EPS due to share issuance. However, the clinical progress of tegoprubart, particularly the positive 24-month Phase 1b data and the high rate of insulin independence in T1D patients, is highly encouraging and de-risks the asset significantly. The Orphan Drug designation further strengthens its market position. Given the substantial dilution and ongoing need for funding, but also the strong clinical momentum, a seasoned investor would likely hold, awaiting further clarity on Phase 3 trial design and future funding strategies.

Keywords

Eledon Pharmaceuticals, ELDN, tegoprubart, anti-CD40L antibody, transplantation, kidney transplant, islet cell transplant, liver transplant, type 1 diabetes, immunosuppression, orphan drug, FDA, clinical trials, biotechnology, financial results, eGFR, HbA1c